Science 37 takes the SPAC shortcut to Nasdaq, landing a $235M windfall for its push on decentralized trials

Science 37, which bills itself as a pioneer in the move to decentralized clinical trials, has reached the end of the SPAC trail to Nasdaq …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sci­ence 37 takes the SPAC short­cut to Nas­daq, land­ing a $235M wind­fall for its push on de­cen­tral­ized tri­als